Washington, D.C. — Senator Tom Cotton (R-Arkansas) today introduced the Anyone But China (ABC) Safe Drug Act, which would end U.S. dependence on China for pharmaceutical manufacturing.

“Shortages in the medical supply chain are a matter of life and death, and we cannot rely on China for our citizens’ survival. This bill will encourage pharmaceutical production in the United States and end dependency on the Chinese Communist Party,” said Cotton.

The bill's key restrictions would go into effect in 2028. No Food and Drug Administration resources will be diverted to begin implementation. Specifically, the bill will:

Prohibit pharmaceutical purchases from China or products with active pharmaceutical ingredients created in China*.
Create transparency in the supply chain by instituting a country-of-origin label of all imported drugs.
Provide economic incentives for manufacturing drugs and medical equipment in the United States.

* This requirement will be phased in over two years. The FDA may issue waivers if the active pharmaceutical ingredients are only available in China, however, no waivers may be issued after 2030.